Joint regeneration in Scottsdale: what to do before a visit

What to bring to a Scottsdale visit

Record the ache's start and point to the exact sore spot. Add old injuries, swelling, catching, and trouble on stairs or in bed.

Take your medicine list and earlier scan reports. Write which home care helped, what didn't help, and how long you tried each step.

Choose one missed task, perhaps a longer walk or the rest of a golf round. That task gives you a plain way to judge later relief.

Wear loose clothing that gives the clinician a full view of the joint. A trusted person can help you remember the answers.

What happens during the visit

First, show the exact place that aches and the moves that cause soreness. The clinician looks at motion, strength, swelling, tender areas, and the way you walk.

Earlier scans can help, but the exam still matters. A scan may show wear that doesn't account for all of your soreness.

The talk may cover home care, therapy, medicine, an office procedure, or surgery. Ask which choice fits now and what finding would change that advice.

Before leaving, repeat the next step in your own words. You need a clear action, not only the name of a product.

What to ask when soreness stays: regenerative medicine Scottsdale and regenerative therapy Scottsdale

Here, those two phrases mean planned clinic procedures prepared from blood or other body tissue. They don't name different kinds of care.

QC Kinetix offers local consultations at 9220 E. Mountain View Rd., Suite 210, Scottsdale, AZ 85258. The clinic phone is (602) 837-PAIN, or (602) 837-7246.

A clinician examines the sore joint before discussing a procedure. Ask what material would be used, how it is prepared, and where the clinician would put it.

Also ask about recovery, cost, follow-up, and the relief being sought. No treatment name can tell you whether your joint will feel better.

From far north Scottsdale, the drive may take roughly 25 to 28 minutes by Pima or Scottsdale Road and Loop 101. Plan the ride home before the visit.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing, topical NSAIDs, oral NSAIDs and intra-articular glucocorticoid injection in knee OA. Notably it does NOT strongly recommend any biologic injectable.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & rheumatology (Hoboken, N.J.), 2020. DOI: 10.1002/art.41142.

2. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

3. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.